An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

This study is looking at a new type of BTK inhibitor called Acalabrutinib. The study specifically focusses on people with WM, with two cohorts: those whose WM has come back or not responded to previous treatment; and those who require treatment but have not had any previous treatment for their WM.

This study is on-going but currently closed to recruitment.